The Tie2 Activator AKB-9778, Used In Combination With Ranibizumab, Enhances Reduction Of Diabetic Macular Edema Compared To Ranibizumab Monotherapy

被引：0
|
作者：
Khanani, Arshad [1 ]
机构：
[1] Sierra Eye Associates, Ophthalmol, Reno, NV USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 9 条
  • [1] Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy
    Brigell, Mitchell G.
    Gonzalez, Victor H.
    Bell, Darren J.
    Khanani, Arshad M.
    Withers, Barbara
    Gambino, Laura
    Campochiaro, Peter A.
    Peters, Kevin G.
    Pakola, Steve
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [2] Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
    Campochiaro, Peter A.
    Khanani, Arshad
    Singer, Michael
    Patel, Sunil
    Boyer, David
    Dugel, Pravin
    Kherani, Saleema
    Withers, Barbara
    Gambino, Laura
    Peters, Kevin
    Brigell, Mitchell
    OPHTHALMOLOGY, 2016, 123 (08) : 1722 - 1730
  • [3] Topical or Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in NZW Rabbits
    Gum, Glenwood G.
    Janusz, John
    Soldo, Brandi
    Walker, Brian
    Buch, Akshay
    Pakola, Steve
    Peters, Kevin G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [4] Comparison of Ranibizumab Monotherapy Versus Combination of Ranibizumab with Focal/Grid Laser Therapy in the Treatment of Diabetic Macular Edema
    Uysal, Aycan
    Fikret, Nil Irem Ucgun Zeki
    Yazar, Zeliha
    Onen, Mehmet
    Fikret, Cenk Zeki
    Sarikatipoglu, Hikmet Yavuz
    OPHTHALMOLOGICA, 2014, 232 : 26 - 26
  • [5] Combination of ranibizumab and navigated retinal photocoagulation in diabetic macular edema, compared to ranibizumab mono-therapy: Twelve month results
    Kernt, M.
    ACTA OPHTHALMOLOGICA, 2013, 91
  • [6] Combination of Ranibizumab and Navigated Retinal Photocoagulation in Diabetic Macular Edema, compared to Ranibizumab Mono-Therapy: Twelve Month Results
    Cserhati, Sarah
    Liegl, Raffael
    Ulbig, Michael
    Haritoglou, Christos
    Kampik, Anselm
    Neubauer, Aljoscha
    Kernt, Marcus
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [7] Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME)
    Berger, Brian B.
    Gale, Jeremy
    Gilbert, Steven
    Popa, Sergei
    Sultan, Marla
    Schachar, Ronald
    Webster, Rob
    Perros-Huguet, Christelle
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [8] A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema
    Brigell, Mitchell G.
    Campochiaro, Peter A.
    Sophie, Raafay
    Tolentino, Michael
    Miller, Daniel
    Browning, David
    Boyer, David S.
    Heier, Jeffrey S.
    Peters, Kevin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [9] Demographics and Baseline Characteristics of the iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center
    Sepah, Yasir
    Do, Diana V.
    Callanan, David
    Gonzalez, Victor H.
    Halperin, Lawrence
    Berger, Brian B.
    Hanout, Mostafa Saad
    Hnik, Peter
    Quan Dong Nguyen
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
1